Intrathecal AAV serotype 9-mediated delivery of shRNA against TRPV1 attenuates thermal hyperalgesia in a mouse model of peripheral nerve injury

Molecular Therapy

Volumn 22, Issue 2, 2014, Pages 409-419

  Hirai, Takashi ^a   Enomoto, Mitsuhiro ^a   Kaburagi, Hidetoshi ^a   Sotome, Shinichi ^a   Yoshida Tanaka, Kie ^a   Ukegawa, Madoka ^a   Kuwahara, Hiroya ^a   Yamamoto, Mariko ^a   Tajiri, Mio ^a   Miyata, Haruka ^a   Hirai, Yukihiko ^b   Tominaga, Makoto ^c   Shinomiya, Kenichi ^a   Mizusawa, Hidehiro ^a   Okawa, Atsushi ^a   Yokota, Takanori ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c OKAZAKI INSTITUTE FOR INTEGRATIVE BIOSCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PARVOVIRUS VECTOR; SHORT HAIRPIN RNA; VANILLOID RECEPTOR 1; MESSENGER RNA; SMALL INTERFERING RNA; TRPV1 PROTEIN, MOUSE; VANILLOID RECEPTOR;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HYPERALGESIA; MOUSE; NONHUMAN; PERIPHERAL NERVE INJURY; SPINAL CORD; SPINAL GANGLION; VIRAL GENE DELIVERY SYSTEM; ADMINISTRATION AND DOSAGE; ANIMAL; CHEMISTRY; DEPENDOPARVOVIRUS; DISEASE MODEL; GENE ORDER; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; IMMUNOLOGY; INTRASPINAL DRUG ADMINISTRATION; METABOLISM; NUCLEOTIDE SEQUENCE; PERIPHERAL NERVE INJURIES; RNA INTERFERENCE;

MUS;

ANIMALS; BASE SEQUENCE; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; FEMALE; GANGLIA, SPINAL; GENE EXPRESSION; GENE ORDER; GENE SILENCING; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HYPERALGESIA; INJECTIONS, SPINAL; MICE; PERIPHERAL NERVE INJURIES; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; SPINAL CORD; TRPV CATION CHANNELS;

EID: 84895911128     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.247     Document Type: Article

References (48)

1. Campbell, JN and Meyer, RA (2006). Mechanisms of neuropathic pain. Neuron 52: 77-92.
2. Finnegan, TF, Chen, SR and Pan, HL (2005). Effect of the {mu} opioid on excitatory and inhibitory synaptic inputs to periaqueductal gray-projecting neurons in the amygdala. J Pharmacol Exp Ther 312: 441-448.
3. Wilson, SP, Yeomans, DC, Bender, MA, Lu, Y, Goins, WF and Glorioso, JC (1999). Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proc Natl Acad Sci USA 96: 3211-3216.
4. Meunier, A, Latrémolière, A, Mauborgne, A, Bourgoin, S, Kayser, V, Cesselin, F et al. (2005). Attenuation of pain-related behavior in a rat model of trigeminal neuropathic pain by viral-driven enkephalin overproduction in trigeminal ganglion neurons. Mol Ther 11: 608-616.
5. Clapham, DE (2003). TRP channels as cellular sensors. Nature 426: 517-524.
6. Levine, JD and Alessandri-Haber, N (2007). TRP channels: targets for the relief of pain. Biochim Biophys Acta 1772: 989-1003.
7. Pogatzki-Zahn, EM, Shimizu, I, Caterina, M and Raja, SN (2005). Heat hyperalgesia after incision requires TRPV1 and is distinct from pure inflammatory pain. Pain 115: 296-307.
8. Yokota, T, Iijima, S, Kubodera, T, Ishii, K, Katakai, Y, Ageyama, N et al. (2007). Efficient regulation of viral replication by siRNA in a non-human primate surrogate model for hepatitis C. Biochem Biophys Res Commun 361: 294-300.
9. Baigude, H, McCarroll, J, Yang, CS, Swain, PM and Rana, TM (2007). Design and creation of new nanomaterials for therapeutic RNAi. ACS Chem Biol 2: 237-241.
10. Nishina, K, Unno, T, Uno, Y, Kubodera, T, Kanouchi, T, Mizusawa, H et al. (2008). Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol Ther 16: 734-740.
11. Rodriguez-Lebron, E, Denovan-Wright, EM, Nash, K, Lewin, AS and Mandel, RJ (2005). Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington′s disease transgenic mice. Mol Ther 12: 618-633.
12. Hirai, T, Enomoto, M, Machida, A, Yamamoto, M, Kuwahara, H, Tajiri, M et al. (2012). Intrathecal shRNA-AAV9 inhibits target protein expression in the spinal cord and dorsal root ganglia of adult mice. Hum Gene Ther Methods 23: 119-127.
13. Decosterd, I and Woolf, CJ (2000). Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 87: 149-158.
14. Calixto, JB, Kassuya, CA, André, E and Ferreira, J (2005). Contribution of natural products to the discovery of the transient receptor potential (TRP) channels family and their functions. Pharmacol Ther 106: 179-208.
15. Chan, CL, Facer, P, Davis, JB, Smith, GD, Egerton, J, Bountra, C et al. (2003). Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency. Lancet 361: 385-391.
16. Schäfers, M, Geis, C, Svensson, CI, Luo, ZD and Sommer, C (2003). Selective increase of tumour necrosis factor-alpha in injured and spared myelinated primary afferents after chronic constrictive injury of rat sciatic nerve. Eur J Neurosci 17: 791-804.
17. Hudson, LJ, Bevan, S, Wotherspoon, G, Gentry, C, Fox, A and Winter, J (2001). VR1 protein expression increases in undamaged DRG neurons after partial nerve injury. Eur J Neurosci 13: 2105-2114.
18. Rasband, MN, Park, EW, Vanderah, TW, Lai, J, Porreca, F and Trimmer, JS (2001). Distinct potassium channels on pain-sensing neurons. Proc Natl Acad Sci USA 98: 13373-13378.
19. Fukuoka, T, Tokunaga, A, Tachibana, T, Dai, Y, Yamanaka, H and Noguchi, K (2002). VR1, but not P2X(3), increases in the spared L4 DRG in rats with L5 spinal nerve ligation. Pain 99: 111-120.
20. Facer, P, Casula, MA, Smith, GD, Benham, CD, Chessell, IP, Bountra, C et al. (2007). Differential expression of the capsaicin receptor TRPV1 and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy. BMC Neurol 7: 11.
21. Obata, K, Katsura, H, Sakurai, J, Kobayashi, K, Yamanaka, H, Dai, Y et al. (2006). Suppression of the p75 neurotrophin receptor in uninjured sensory neurons reduces neuropathic pain after nerve injury. J Neurosci 26: 11974-11986.
22. Hwang, SJ, Burette, A, Rustioni, A and Valtschanoff, JG (2004). Vanilloid receptor VR1-positive primary afferents are glutamatergic and contact spinal neurons that coexpress neurokinin receptor NK1 and glutamate receptors. J Neurocytol 33: 321-329.
23. Kosugi, M, Nakatsuka, T, Fujita, T, Kuroda, Y and Kumamoto, E (2007). Activation of TRPA1 channel facilitates excitatory synaptic transmission in substantia gelatinosa neurons of the adult rat spinal cord. J Neurosci 27: 4443-4451.
24. Ferrini, F, Salio, C, Vergnano, AM and Merighi, A (2007). Vanilloid receptor-1 (TRPV1)- dependent activation of inhibitory neurotransmission in spinal substantia gelatinosa neurons of mouse. Pain 129: 195-209.
25. Kim, YH, Back, SK, Davies, AJ, Jeong, H, Jo, HJ, Chung, G et al. (2012). TRPV1 in GABAergic interneurons mediates neuropathic mechanical allodynia and disinhibition of the nociceptive circuitry in the spinal cord. Neuron 74: 640-647.
26. Ossipov, MH, Bian, D, Malan, TP Jr, Lai, J and Porreca, F (1999). Lack of involvement of capsaicin-sensitive primary afferents in nerve-ligation injury induced tactile allodynia in rats. Pain 79: 127-133.
27. Caterina, MJ, Leffler, A, Malmberg, AB, Martin, WJ, Trafton, J, Petersen-Zeitz, KR et al. (2000). Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288: 306-313.
28. Culshaw, AJ, Bevan, S, Christiansen, M, Copp, P, Davis, A, Davis, C et al. (2006). Identification and biological characterization of 6-aryl-7-isopropylquinazolinones as novel TRPV1 antagonists that are effective in models of chronic pain. J Med Chem 49: 471-474.
29. Christoph, T, Grünweller, A, Mika, J, Schäfer, MK, Wade, EJ, Weihe, E et al. (2006). Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo. Biochem Biophys Res Commun 350: 238-243.
30. Klusáková, I and Dubový, P (2009). Experimental models of peripheral neuropathic pain based on traumatic nerve injuries - an anatomical perspective. Ann Anat 191: 248-259.
31. Davis, JB, Gray, J, Gunthorpe, MJ, Hatcher, JP, Davey, PT, Overend, P et al. (2000). Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 405: 183-187.
32. Jordt, SE, McKemy, DD and Julius, D (2003). Lessons from peppers and peppermint: the molecular logic of thermosensation. Curr Opin Neurobiol 13: 487-492.
33. Patapoutian, A, Peier, AM, Story, GM and Viswanath, V (2003). ThermoTRP channels and beyond: mechanisms of temperature sensation. Nat Rev Neurosci 4: 529-539.
34. Moran, MM, Xu, H and Clapham, DE (2004). TRP ion channels in the nervous system. Curr Opin Neurobiol 14: 362-369.
35. Tominaga, M and Caterina, MJ (2004). Thermosensation and pain. J Neurobiol 61: 3-12.
36. Vriens, J, Owsianik, G, Hofmann, T, Philipp, SE, Stab, J, Chen, X et al. (2011). TRPM3 is a nociceptor channel involved in the detection of noxious heat. Neuron 70: 482-494.
37. Cho, H, Yang, YD, Lee, J, Lee, B, Kim, T, Jang, Y et al. (2012). The calcium-activated chloride channel anoctamin 1 acts as a heat sensor in nociceptive neurons. Nat Neurosci 15: 1015-1021.
38. Shimosato, G, Amaya, F, Ueda, M, Tanaka, Y, Decosterd, I and Tanaka, M (2005). Peripheral inflammation induces up-regulation of TRPV2 expression in rat DRG. Pain 119: 225-232.
39. Park, U, Vastani, N, Guan, Y, Raja, SN, Koltzenburg, M and Caterina, MJ (2011). TRP vanilloid 2 knock-out mice are susceptible to perinatal lethality but display normal thermal and mechanical nociception. J Neurosci 31: 11425-11436.
40. Moqrich, A, Hwang, SW, Earley, TJ, Petrus, MJ, Murray, AN, Spencer, KS et al. (2005). Impaired thermosensation in mice lacking TRPV3, a heat and camphor sensor in the skin. Science 307: 1468-1472.
41. Suhy, DA, Kao, SC, Mao, T, Whiteley, L, Denise, H, Souberbielle, B et al. (2012). Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model. Mol Ther 20: 1737-1749.
42. Janson, C, McPhee, S, Bilaniuk, L, Haselgrove, J, Testaiuti, M, Freese, A et al. (2002). Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther 13: 1391-1412.
43. Kaplitt, MG, Feigin, A, Tang, C, Fitzsimons, HL, Mattis, P, Lawlor, PA et al. (2007). Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson′s disease: an open label, phase I trial. Lancet 369: 2097-2105.
44. Boutin, S, Monteilhet, V, Veron, P, Leborgne, C, Benveniste, O, Montus, MF et al. (2010). Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 21: 704-712.
45. Bartel, M, Schaffer, D and Büning, H (2011). Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity. Front Microbiol 2: 204.
46. Kappel, S, Matthess, Y, Kaufmann, M and Strebhardt, K (2007). Silencing of mammalian genes by tetracycline-inducible shRNA expression. Nat Protoc 2: 3257-3269.
47. Yokota, T, Miyagishi, M, Hino, T, Matsumura, R, Tasinato, A, Urushitani, M et al. (2004). siRNA-based inhibition specific for mutant SOD1 with single nucleotide alternation in familial ALS, compared with ribozyme and DNA enzyme. Biochem Biophys Res Commun 314: 283-291.
48. Hargreaves, K, Dubner, R, Brown, F, Flores, C and Joris, J (1988). A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32: 77-88.